Azithromycin for Acute Exacerbations of Asthma: The AZALEA Randomized Clinical Trial by Johnston, Sebastian L. et al.
1 
 
The Azithromycin for Acute Exacerbations of Asthma (AZALEA) Randomized Clinical Trial  1 
 2 
Sebastian L. Johnston1* MBBS, PhD, Matyas Szigeti2 MSc, Mary Cross2 BA (Hons), Christopher 3 
Brightling3 MBBS, PhD, Rekha Chaudhuri4, 5 MBBS, MD, Timothy Harrison6 MBBS, PhD, Adel 4 
Mansur7, 8 MBBS, PhD, Laura Robison2 BSc, Zahid Sattar2 BSc, PhD, David Jackson1 MBBS, PhD, 5 
Patrick Mallia1 MBBS, PhD, Ernie Wong1 MBBS, BSc, Christopher Corrigan9, 10 MA, PhD, Bernard 6 
Higgins11 MBBS, Philip Ind1, 12 MB BChir, PhD, Dave Singh13 MB BChir, MD, Neil C. Thomson4 7 
MBChB, MD, Deborah Ashby2 PhD, CStat, Anoop Chauhan14 MBBS, PhD on behalf of the 8 
AZALEA Trial Team. 9 
 10 
1 National Heart and Lung Institute, Imperial College London, London, UK 11 
2 Imperial Clinical Trials Unit, School of Public Health, Imperial College London, London, UK 12 
3 Institute for Lung Health, University of Leicester, Leicester, UK 13 
4 Institute of Infection Immunity and Inflammation, University of Glasgow, Glasgow, UK 14 
5 Respiratory Medicine, NHS Greater Glasgow and Clyde, Glasgow, UK 15 
6 Nottingham Respiratory Research Unit, University of Nottingham, Nottingham, UK 16 
7 Respiratory Medicine, Heart of England Foundation Trust, Birmingham, UK 17 
8 Severe and Brittle Asthma Unit, University of Birmingham, Birmingham, UK 18 
9 Respiratory Medicine & Allergy, King’s College London School of Medicine, London, UK 19 
10 Department of Asthma, Allergy and Respiratory Science, Guy’s & St. Thomas’ NHS 20 
Foundation Trust, London, UK 21 
11 Respiratory Medicine, Newcastle University, Newcastle, UK 22 
12 Respiratory Medicine, Imperial College Healthcare NHS Trust, London, UK 23 
13 Centre for Respiratory Medicine and Allergy, Medicines Evaluation Unit, University of 24 
Manchester and University Hospital of South Manchester NHS Foundation Trust, 25 
Manchester, UK 26 
2 
 
14 Respiratory Medicine, Portsmouth Hospitals NHS Trust, Portsmouth, UK 27 
 28 
*Corresponding author: Professor Sebastian Johnston, Airway Disease Infection Section, 29 
National Heart and Lung Institute, Imperial College London, Norfolk Place, London W2 1PG; e 30 
mail: s.johnston@imperial.ac.uk, telephone: +44 20 7594 3764, fax: +44 20 7262 8913. 31 
 32 
Authors’ contributions: Sebastian Johnston conception and design of study, analysis and 33 
interpretation of data, drafting/revising report, approval of report, guarantor for the study 34 
Matyas Szigeti, Laura Robison, Zahid Sattar, David Jackson, Patrick Mallia, Ernie Wong, Deborah 35 
Ashby: analysis and interpretation of data, drafting/revising report, approval of report 36 
Mary Cross: design of study, analysis and interpretation of data, drafting/revising report, approval of 37 
report 38 
Christopher Brightling, Rekha Chaudhuri, Timothy Harrison, Adel Mansur, Christopher Corrigan, 39 
Bernard Higgins, Philip Ind, Dave Singh, Neil Thomson, Anoop Chauhan: conception and design of 40 
study, analysis and interpretation of data, drafting/revising report, approval of report 41 
 42 
Conflict of interest disclosures: 43 
Sebastian Johnston:  Institutional funding for a clinical trial, research grant and/or Consultant 44 
compensation: AstraZeneca, Boehringer Ingelheim, Centocor, Chiesi, GlaxoSmithKline, Merck, 45 
Novartis, Roche/Genentech, Sanofi Pasteur & Synairgen; Shareholding: Synairgen; Licensed 46 
Patents: 9; Patents Pending: 1 47 
Christopher Brightling: Grants and consultancy paid to Institution from: GSK, AstraZeneca, 48 
Boehringer Ingelheim, Novartis, Chiesi and Roche/Genentech 49 
Rekha Chaudhuri: Grant and Personal Fees for attendance at scientific conferences and advisory 50 
board meetings: Novartis Pharmaceuticals, Astra-Zeneca, Teva, GlaxoSmithkline 51 
3 
 
Dave Singh: Grants and personal fees from:  Almirall, AstraZeneca, Boehringher Ingleheim, Chiesi, 52 
GlaxoSmithKline, Glenmark, Johnson and Johnson, Merck, NAPP, Novartis, Pfizer, Takeda, Teva, 53 
Therevance & Verona. Personal fees from: Genentech & Skyepharma. 54 
Bernard Higgins: Multicentre Study, local PI for studies funded by: Novartis & Roche 55 
Christopher Corrigan: Grant and Personal Fees for attendance at scientific conferences and payments 56 
for lectures: Allergy Therapeutics; Grant and Personal Fees for research collaborations and 57 
consultancy not connected with the current research: Novartis; Grant for attendance at scientific 58 
conferences: Stallergenes, Boehringer Ingelheim & Diagenics; Personal fees for speaking at 59 
conferences: Astra Zeneca 60 
All other authors: None 61 
 62 
Main text word count 3000. 63 
Key words: Asthma, Asthma Exacerbation, Antibiotic, Randomized, Controlled Trial 64 
Trial registration: ClinicalTrials.gov Identifier:  NCT01444469 65 
Funding: This project was funded by the Efficacy and Mechanism Evaluation programme of the 66 
Medical Research Council and the National Institute of Health Research, UK.  Funders Reference 67 
number: 10/60/27 68 
The AZALEA Trial team membership and their affiliations are listed in the Online Supplement. 69 
Disclaimer: The views expressed in this article are those of the authors and not necessarily those of 70 
the National Health Service, the National Institute for Health Research (NIHR), or the Department of 71 
Health.   72 
4 
 
Abstract 73 
Importance: Guidelines recommend against antibiotic use to treat asthma attacks. A study with 74 
telithromycin reported benefit, but adverse reactions limit its use.  75 
Objective: To determine whether azithromycin added to standard care of asthma attacks in adults 76 
resulted in clinical benefit. 77 
Design: The AZithromycin Against pLacebo in Exacerbations of Asthma (AZALEA) randomized, 78 
double-blind, placebo-controlled clinical trial ran from September 2011 to April 2014. 79 
Setting: UK-based multi-center study in adults requesting emergency care for acute asthma 80 
exacerbations. 81 
Participants: Adults with a history of asthma for >6 months, recruited within 48 hours of 82 
presentation to medical care with an acute deterioration in asthma control requiring a course of 83 
oral/systemic corticosteroids.  84 
Intervention: Azithromycin 500mg daily or matched placebo for 3 days. 85 
Main Outcomes: The primary outcome was diary card symptom score 10 days after randomization, 86 
with an hypothesized treatment effect size of -0.3. Secondary outcomes were diary card symptom 87 
score, quality of life questionnaires and lung function changes between exacerbation and day 10, and 88 
time to 50% reduction in symptom score. 89 
Results: Of 4582 patients screened at 31 centers, 199 of a planned 380 were randomized within 48 90 
hours of presentation. The major reason for non-recruitment was receiving antibiotics (2044, 44.6% 91 
of screened subjects). Median time from presentation to drug administration was 22 hours. 92 
Exacerbation characteristics were well balanced across treatment arms and centers. The primary 93 
outcome asthma symptom scores in this likely underpowered study were: mean (SD) 4.14 (1.38) at 94 
exacerbation and 2.09 (1.71) at 10 days for azithromycin; 4.18 (1.48) and 2.20 (1.51) for placebo. 95 
Using multilevel modeling, there was no significant difference in symptom scores between 96 
azithromycin and placebo at day 10 (difference -0.166 [95% confidence interval -0.670 to 0.337]), 97 
nor on any day between exacerbation and day 10. No significant between group differences were 98 
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observed in quality of life questionnaires or lung function between exacerbation and day 10, or in 99 
time to 50% reduction in symptom score. 100 
Conclusions: In this randomized population, azithromycin resulted in no statistically or clinically 101 
significant benefit. For each patient randomized, >10 failed screening because they had already 102 
received antibiotics.  103 
Trial Registration: ClinicalTrials.gov Identifier:  NCT01444469, 104 
https://clinicaltrials.gov/ct2/show/NCT01444469?term=AZALEA&rank=1 105 
 106 
Word count:  347 words (including headings) 107 
  108 
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List of abbreviations  109 
 110 
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AQLQ  Asthma quality of life questionnaire 120 
  121 
7 
 
Background 122 
Asthma morbidity, mortality and major health care costs result from acute attacks (exacerbations)1. 123 
The majority of asthma patients report an exacerbation in the last year, with >1/3 children and >1/4 124 
adults requiring consequent urgent medical care2.  125 
Respiratory viral infections are a frequent cause of asthma exacerbations in children3,4 and adults5-7. 126 
Atypical bacterial (Mycoplasma and Chlamydophila (C.) pneumoniae) infection/reactivation is also 127 
associated, with serologic positivity rates of 40-60% in some studies8-12, indicating viral and atypical 128 
bacterial infections may interact in increasing asthma exacerbation risk. 129 
People with asthma have increased susceptibility to streptococcal infections13-15, increased carriage 130 
of bacterial pathogens identified by culture16 and molecular techniques17 and impaired interferon/Th1 131 
responses to bacterial polysaccharides18,19. Viral infection impairs antibacterial innate immune 132 
responses20 and increases bacterial adherence to bronchial epithelium21. Thus, bacterial infections are 133 
more common and more severe in asthma, viruses increase susceptibility to bacterial infection and 134 
acute wheezing episodes in children aged <3 years were associated with both bacterial and virus 135 
infection22.  136 
Asthma exacerbations treated with telithromycin had greater reductions in asthma symptoms, 137 
improvement in lung function and faster recovery compared to placebo12. However, liver toxicity 138 
limits telithromycin to life threatening infections and guidelines recommend antibiotics should NOT 139 
be administered routinely in asthma exacerbations23,24. 140 
The AZALEA study investigated the effectiveness of azithromycin when added to standard care for 141 
adult patients with asthma exacerbations, closely following the telithromycin study design, with the 142 
aim of providing confirmation or otherwise of those results. 143 
Macrolide antibiotics might benefit asthma exacerbations through antimicrobial activity, anti-144 
inflammatory properties25 and azithromycin, but not telithromycin, was anti-viral26 augmenting 145 
production of interferons that are deficient in asthma19,27. A mechanistic/exploratory aim of 146 
AZALEA was to determine whether treatment benefitted patients with these infections. 147 
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Methods  148 
Study design 149 
This United Kingdom-based multi-center, double-blind, placebo-controlled study randomized 150 
eligible patients to azithromycin 500mg daily or placebo for 3 days on day 1 (Visit 1), with post-151 
therapy assessments/visits on days 5 (Visit 2) and 10 (Visit 3) and for serum sampling at six weeks 152 
(Visit 4). 153 
The main inclusion criteria were adults aged 18-55 years with any smoking history, aged 56-65 with 154 
<20 pack year smoking history or >65 years with <5 pack year smoking history with a documented 155 
history of asthma for >6 months, and recruitment within 48 hours of presentation to medical care 156 
with an acute deterioration in asthma control (increased wheeze, dyspnea and/or cough) requiring a 157 
course of oral/systemic corticosteroids (based on clinical judgement by attending physicians) and a peak 158 
expiratory flow (PEF) or forced expiratory volume in one second (FEV1) less than 80% predicted or 159 
patient’s best at presentation, at recruitment or in the time elapsed between presentation and 160 
recruitment.  161 
The main exclusion criteria were use of oral/systemic antibiotics within 28 days of enrolment, need 162 
for intensive care, significant lung disease other than asthma, chronic use of >20mg oral 163 
corticosteroid daily, known QT-interval prolongation, history of brady/tachy arrhythmias or 164 
uncompensated heart failure and patients on drugs known to prolong the QT interval.  165 
The primary outcome was diary card summary symptom score, with symptoms including wheezing, 166 
breathlessness and coughing assessed at 10 days after randomization (as in the telithromycin 167 
study)12. Secondary outcomes included the acute Asthma Quality of Life Questionnaire (AQLQ), the 168 
mini AQLQ, FEV1, forced vital capacity (FVC), FEV1/FVC, forced mid-expiratory flow (FEF25-75%), 169 
forced expiratory flow at 50% expiration (FEF50%), PEF and time to 50% reduction in symptom 170 
score. Primary and secondary outcomes were assessed over the time course of the exacerbation to 10 171 
days and sub-group analyses were planned in relation to initial standard/atypical bacteriologic and 172 
virologic status.  173 
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Spontaneous or induced sputum was taken where possible at exacerbation and sent for quantitative 174 
bacteria culture. A nasal mucus sample, nasal and throat swabs were taken where possible at 175 
exacerbation and these and spontaneous/induced sputum were analyzed by viral and atypical 176 
bacterial PCRs and acute and convalescent sera for atypical bacterial serology.  177 
The trial received Research Ethics Committee approval and all patients gave written informed 178 
consent. Additional methods are available in the Online Supplement. 179 
Statistical analyses 180 
The sample size calculations hypothesized a treatment effect size of -0.3 (SD 0.783) based on the 181 
primary outcome of the telithromycin study12 and used a significance level of 1% with 80% power, 182 
assuming a drop-out rate of 15%12. We proposed to recruit 190 patients to each arm. To run the trial 183 
within the project funding one-year timeline, we planned 10 centers, each recruiting ~38 patients.  184 
All patients who returned at least one diary card and received study drug were included in the 185 
intention-to-treat analyses. As the timing of greatest magnitude of any treatment effect was not 186 
known, multilevel modelling was used to calculate the estimated differences in primary and 187 
secondary outcomes between treatment arms for each day from randomization to day 10. A Cox 188 
model was used to calculate the hazard ratio for time to 50% reduction in symptom score. Details of 189 
the statistical model, model selection process and treatment of missing data are in the Online 190 
Supplement. All analyses were performed using Stata 13. A Statistical Analysis Plan was prepared 191 
by the trial statistician prior to unblinding.  192 
  193 
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Results 194 
Recruitment details and clinical characteristics 195 
Recruitment from 31 sites (30 secondary care hospitals, 1 primary care center) lasted 2.5 years, from 196 
September 2011 to April 2014. The recruitment period was longer than planned because of 197 
recruitment difficulties arising from the large numbers of patients excluded. A total of 4582 patients 198 
were screened of whom 390 patients met eligibility criteria, 199 were randomized, 97 to active 199 
treatment, 102 to placebo (Figure 1). The major reason for non-recruitment was already receiving 200 
antibiotics (2044, 44.6% of screened patients).  201 
Clinical characteristics of randomized patients are summarized in Table 1. Study participants’ mean 202 
age was 39.9 years, gender 69.8% female, 30.2% male. Underlying asthma severity, smoking status, 203 
exacerbation severity and median time from presentation to trial drug administration are in Table 1. 204 
Pulmonary function at baseline (exacerbation, Visit 1) are in Table 2 and include PEF 74.8% 205 
predicted, FEV1 64.8% predicted, and FEV1/FVC 69.2% (all means). Baseline characteristics were 206 
well balanced across treatment arms and centers. 207 
Of the 199 patients randomized, all attended visit 1 (randomization), 21 (11%) missed Visit 2, 28 208 
(14%) missed Visit 3 and 39 (20%) missed Visit 4, 80% of patients attended all follow-up visits. 209 
Missing visits/data were balanced between the treatment arms. Day 1 was defined as the day of 210 
administration of study drug.  211 
Primary outcome analysis 212 
Mean (SD) asthma symptom scores (from 0=no symptoms to 6=severe symptoms) were 4.14 (1.38) 213 
at baseline (exacerbation) and 2.09 (1.71) at day 10 for azithromycin and 4.18 (1.48) and 2.20 (1.51) 214 
respectively for placebo. Using multilevel modeling, there was no statistically significant difference 215 
in symptom scores between groups at day 10 (difference -0.166 [95% CI: -0.670; 0.337], Figure 2 216 
and Online Supplement eTable 3). 217 
Secondary outcome analyses 218 
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Multilevel modeling revealed no significant between group differences in symptom scores on any 219 
day between baseline and day 10 .(Figure 2 and Online Supplement eTable 3). 220 
No significant between group differences were seen in acute AQLQ, mini AQLQ (Figure 3a and 3b 221 
and Online Supplement eTables 7-10) nor in any measure of lung function (Online Supplement 222 
eTables 11 and 12) on any day from baseline to day 10 and there was no difference in time to 50% 223 
reduction in symptom score (Hazard Ratio 1.03 [95% CI: 0.71; 1.49]) (Figure 3c). 224 
Pathogen detection results 225 
105 (52.7%) patients provided sputum for bacterial culture, 191 (96.0%) nasal/throat mucus/swabs 226 
for virus/atypical bacterial PCR and 158 (79.4%) acute (IgM) and acute and convalescent (IgG, IgA) 227 
sera for atypical bacterial serology. 228 
A bacterial/atypical bacterial test positive occurred in 10.6% of patients (9.3% active, 11.8% 229 
placebo). Nasal/throat swab/mucus and/or sputum virus PCRs were positive in 18.1% of patients 230 
(16.5% active, 19.6% placebo).  231 
Subgroup analyses 232 
There were no differences in the primary outcome asthma symptom score between treatment groups 233 
in patients with positive sputum bacterial culture, atypical bacterial PCR/serology or virus PCR tests 234 
(including any bacteria/virus positive test) (Online Supplement eTables 13-15 and Online 235 
Supplement eFigures 6-8), though patient numbers for these analyses were low.  236 
Safety 237 
Adverse events were infrequent (Online Supplement eTables 16-22), with more gastrointestinal 238 
adverse events in the azithromycin group compared to placebo (35 vs 24 events respectively Online 239 
Supplement eTable 16). There was an increased frequency of cardiac adverse events (4 vs 2 240 
respectively) in the azithromycin group compared to placebo and a reduced frequency of respiratory, 241 
thoracic and mediastinal (63/64 respiratory) adverse events (27 vs 37 respectively) Online 242 
Supplement eTables 16 and 20), suggesting antibiotic therapy possibly reduced respiratory adverse 243 
events in this population.   244 
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Discussion 245 
In the patients with asthma exacerbations randomized to treatment/placebo in this study, addition of 246 
azithromycin to standard medical care resulted in no statistically or clinically significant therapeutic 247 
benefit. The findings were consistently negative across three different symptom and quality of life 248 
scores, including one previously reporting statistically and clinically significant benefit with 249 
telithromycin12. The findings were also negative for all measures of lung function, including FEV1 250 
which was significantly improved in the previous study12 and for time to a 50% reduction in asthma 251 
symptoms, which was significantly improved in the previous study12.  252 
Recruitment proved extremely challenging; initially there were 10 centers each aiming to recruit 38 253 
subjects over one winter season, to recruit the planned 380 patients. Our power calculation 254 
deliberately mandated large patient numbers to provide statistically robust data to settle the important 255 
clinical question regarding antibiotic efficacy in this setting (for comparison the telithromycin study 256 
randomized 270 patients)12. We also desired larger patient numbers to enhance subgroup analyses 257 
aimed at potentially important mechanistic questions. Once recruitment obstacles became clear with 258 
such widespread antibiotic usage, a total of 31centers were enrolled, inclusion criteria were relaxed 259 
to change eligibility criteria from <24 to <48 hours from time of presentation, to include older 260 
subjects with low smoking histories and recruitment was extended to 2 years and 7 months. 261 
However, despite all these efforts only 199 subjects were recruited by medication-expiry and 262 
funding-end dates and the study was terminated despite not reaching its recruitment target. The study 263 
was therefore underpowered and a difference of 0.3 in mean symptom score between treatment arms 264 
at 10 days cannot be excluded.   265 
The different outcomes of the present and previous study12, which employed closely related therapies 266 
in very similar study designs, requires interpretation/explanation. The antibiotics studied are 267 
different, albeit related. Both drugs were used at their standard recommended doses and durations of 268 
therapy. The shorter duration of treatment with azithromycin (3 days vs 10 days with telithromycin) 269 
is unlikely to explain the difference in outcome, as azithromycin has a very long tissue half-life and 270 
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is likely to have remained at therapeutic doses in the lung for around 10 days28. Azithromycin, but 271 
not telithromycin has anti-viral activity26, so this is an unlikely explanation. In terms of anti-bacterial 272 
activity against relevant respiratory bacteria, telithromycin is reportedly more active than 273 
azithromycin against S. pneumoniae, but has similar activity against both M. catarrhalis and H. 274 
influenzae29-31. Since the present study only detected 3 S. pneumoniae, 1 M. catarrhalis and no H. 275 
influenzae infections in the active treatment arm, differences in activity against these organisms seem 276 
unlikely to explain the differing outcomes. In terms of anti-inflammatory activities, both drugs 277 
reportedly have similar activities when compared25.  278 
A remarkable finding of this study was the number of patients (2044) excluded as they were already 279 
receiving antibiotic therapy for their asthma exacerbation, despite treatment guidelines 280 
recommending such therapy should not be routinely given23,24. For each patient randomized, more 281 
than 10 were excluded for this reason. This important finding has obvious and worrying implications 282 
regarding antibiotic stewardship32, in addition, such high antibiotic usage may also have directly 283 
influenced study outcome as it is possible that patients who might potentially have benefitted from 284 
antibiotic therapy for their asthma exacerbation (through having sputum production, sputum 285 
purulence, fever), were excluded from the study through already having received them. The 286 
population remaining to be randomized could theoretically have been selected against for antibiotic 287 
responsiveness, through having no clinical indication that antibiotic therapy might be of benefit. This 288 
is possible as patients being screened had often been seen by their primary care practitioner, by 289 
emergency room medical staff and by a member of the on call respiratory/medical team, so in many 290 
instances three independent doctors/teams had assessed them, including their suitability for 291 
antibiotics. It is likely therefore that those not prescribed antibiotics were negatively selected against, 292 
for suitability for antibiotics. This interpretation is supported by the very low bacterial/atypical 293 
bacterial positivity rate found in this study: only 9.3% of azithromycin treated subjects. 294 
It is also possible that the population randomized were in other ways not representative of the larger 295 
population screened, as over 2000 other patients were excluded from the study for other reasons 296 
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(Figure 1). The telithromycin study did not report numbers of patients screened12, so it is not 297 
possible to determine to what extent these caveats may also have applied to that study. 298 
A further difference is that all patients randomized to this study were required to be prescribed 299 
oral/systemic corticosteroid treatment, while in the telithromycin study only 34.1% of patients 300 
randomized to active treatment required corticosteroid therapy12. Requirement for corticosteroid 301 
treatment in this study was designed to reduce the number of milder exacerbations studied. However, 302 
if our study included largely non-bacterially infected subjects, this could have resulted in us studying 303 
possible anti-inflammatory effects of azithromycin, in the face of the powerful anti-inflammatory 304 
effects of corticosteroids, with predictably negative results.  305 
The clinical characteristics of the patients in our study compared to those in the telithromycin study 306 
were similar in terms of mean age (39.9 years in our study, vs 39.5 in the telithromycin study), 307 
gender (30.2% male vs 32%), smoking status (mean of 3.44 pack years vs 2.15), exacerbation 308 
symptom score severity (4.16 vs 2.9) and lung function at exacerbation (PEF 74.8% predicted vs 309 
55.2%, FEV1 64.8% predicted vs 67.2%, FEV1/FVC 69.2% vs 72%)12. Differences in clinical 310 
characteristics do not seem a likely explanation for the difference in outcome of the two studies.  311 
The studies differed strikingly in one regard: 61% of telithromycin-treated but only 5.2% of 312 
azithromycin-treated patients had a positive test for current atypical bacterial infection12. Both 313 
studies used similar sampling and detection methods, though the laboratories performing the analyses 314 
differed (GR Micro, London UK for telithromycin, Prof Johnston’s laboratory for this study). PCR 315 
detection rates were very low in both studies (3 positive in the telithromycin study and 0 positive in 316 
this study). In contrast, serological positives differed markedly: the telithromycin study positives 317 
were almost all C. pneumoniae IgM positives, while in our study only one sample was IgM positive 318 
for this organism. Both studies used the same assay (Medac C. pneumoniae IgM sandwich ELISA, 319 
Medac, Hamburg, Germany) so the discrepancy between the results of this assay is difficult to 320 
explain. This major difference in frequency of C. pneumoniae IgM positivity may have contributed 321 
to the difference in clinical outcomes between the two studies. 322 
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Sputum culture for standard bacteria was not performed in the telithromycin study12. In the present 323 
study 105 (52.8%) subjects provided sputum for bacterial culture and positivity was observed in 324 
6.0% (4.1% active, 7.8% placebo), These results, together with the negative outcomes in relation to 325 
therapy, suggest that the role of standard bacterial infection in the population studied was unlikely to 326 
be important. 327 
Interpretation of the outcome of this study must be considered in the light of prior knowledge that 328 
non-infectious agents can also trigger exacerbations, and of other randomized placebo controlled 329 
studies investigating the effects of similar therapies in acute wheezing episodes. In addition to the 330 
telithromycin study reporting positive outcomes in asthma exacerbations in adults12, azithromycin 331 
treatment during bronchiolitis in infancy was reported to reduce nasal lavage IL-8, the occurrence of 332 
post-bronchiolitic wheezing33 and the duration of acute episodes of asthma-like symptoms in 1-3 333 
year old children34. Furthermore, in 1-6 year old children with histories of recurrent severe lower 334 
respiratory tract infections (LRTIs), azithromycin early during an apparent RTI reduced the 335 
likelihood of severe LRTI35. Finally low-dose azithromycin prophylaxis for 6 months in subjects 336 
with exacerbation-prone severe asthma did not reduce the primary outcome (rate of severe 337 
exacerbations and LRTIs requiring treatment with antibiotics) however in a predefined subgroup 338 
analysis according to inflammatory phenotype, azithromycin benefitted subjects with non-339 
eosinophilic severe asthma36. We therefore carried out a similar post hoc analysis, but found no 340 
evidence of benefit in this subgroup (Online Supplement). Thus further study of azithromycin in 341 
acute exacerbations of asthma in adults and children in settings of low antibiotic usage and 342 
stratifying on blood/sputum cell counts seems justified. 343 
In conclusion, in the patients randomized to treatment/placebo in this study, addition of azithromycin 344 
to standard medical care resulted in no statistically significant, or clinically important benefit. For 345 
each patient randomized, more than 10 were excluded because they had already received antibiotics.  346 
347 
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Figure legends 450 
 451 
Figure 1. CONSORT diagram of the AZALEA trial. 452 
 453 
Figure 2: Primary outcome symptom diary scores from randomization to day 10. 454 
Data are mean with standard error (SE) bars. 455 
 456 
Figure 3: Secondary outcome acute and mini AQLQ scores from randomization to day 10 and 457 
time to 50% reduction in symptom diary score.  458 
(a) Acute AQLQ and (b) mini AQLQ mean scores and standard error (SE) bars by visits for each 459 
treatment arm and (c) Kaplan-Meier curves of time to a 50% reduction in symptom diary score for 460 
each treatment arm (truncated at 10 days).  461 
 462 
 463 
  464 
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Table 1: Baseline characteristics of 
patients by treatment group Active Placebo 
N 97 102 
Age (years), median (IQR) 39.1 (28.9, 49.5) 36.15 (25.4, 49.3) 
Gender 
   Female 64 (66.0%) 75 (73.5%) 
   Male 33 (34.0%) 27 (26.5%) 
Asthma Severity (N = 198)37 
   step 1: mild intermittent asthma 7 (7.2%) 13 (12.9%) 
   step 2: regular preventer therapy 30 (30.9%) 26 (25.7%) 
   step 3: initial add-on therapy 31 (32.0%) 27 (26.7%) 
   step 4: persistent poor control 22 (22.7%) 22 (21.8%) 
   step 5: continuous/frequent oral steroids 7 (7.2%) 13 (12.9%) 
Smoking status 
   never smoked 60 (61.9%) 61 (60.4%) 
   former smoker 26 (26.8%) 19 (18.8%) 
   current smoker 11 (11.3%) 21 (20.8%) 
Pack years, median (IQR) (min/max) (N=75)* 
(current/former smokers) 
5 (1, 15) 
(0/127) 
5 (2, 12) 
(0/22) 
Asthma Exacerbation (N = 198) 
   Mild Asthma Exacerbation 5 (5.2%) 3 (3.0%) 
   Moderate Asthma Exacerbation 26 (26.8%) 35 (34.7%) 
   Acute Severe Asthma 61 (62.9%) 56 (55.4%) 
   Life Threatening Asthma 4 (4.1%) 7 (6.9%) 
   Near-Fatal Asthma 1 (1.0%) 0 (0.0%) 
Time from presentation to study drug, median 
(IQR) (N = 192) 21 (12, 29) 22 (14, 28) 
  465 
21 
 
Table2: Baseline (exacerbation) pulmonary function by treatment arm 466 
Active 
              
Pulmonary function N Mean SD P25 Median P75 
FEV1(liters) 95 1.9 0.7 1.4 1.8 2.5 
FEV1 %predicted (%) 93 63.2 21.8 48 63 79 
FVC(liters) 96 2.8 1.0 2.0 2.7 3.5 
FEV1/FVC ratio 94 69.7 13.3 62.0 70.0 79.0 
FEF25-75%(liters/sec) 80 1.6 0.9 0.9 1.4 2.1 
FEF50%(liters/sec) 76 1.9 1.1 1.1 1.7 2.6 
PEF(liters/min) 95 288 108 211 283 361 
PEF %predicted (%) 94 76.6 108.6 47.0 67.5 79.0 
Placebo 
Pulmonary function N Mean SD P25 Median P75 
FEV1(liters) 96 2.1 0.8 1.5 2.0 2.6 
FEV1 %predicted (%) 96 66.3 21.0 52.5 64.0 84.0 
FVC(liters) 96 3.1 1.0 2.4 3.0 3.6 
FEV1/FVC ratio 96 68.8 13.7 58.0 69.0 79.5 
FEF25-75%(liters/sec) 87 1.7 1.1 0.9 1.4 2.4 
FEF50%(liters/sec) 84 2.0 1.3 1.1 1.7 2.8 
PEF(liters/min) 97 320 102 247 335 389 
PEF %predicted (%) 96 72.9 21.4 56.5 74.0 90.0 
SD = standard deviation, P25 = 25th percentile, P75 = 75th  percentile 467 
Figure 1. CONSORT diagram of the AZALEA trial 
  
 
Figure 2: Primary outcome symptom diary scores from randomization to day 10. 
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Figure 3: Secondary outcome acute and mini AQLQ scores from randomization to day 
10 and time to 50% reduction in symptom diary score.  
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